MedPharm Adds First-to-File Generic Topical Drug to Commercial Manufacturing Portfolio
Key Points
- MedPharm will manufacture and supply a first-to-file generic topical drug product under a new commercial agreement, its sixth commercial deal in 22 months.
- The program expands MedPharm's commercial portfolio into first-to-file generic topical products.
- Manufacturing will take place at MedPharm's 110,000-square-foot Durham, North Carolina facility, which offers dedicated production infrastructure and analytical testing.
MedPharm has expanded its commercial manufacturing business with a new agreement to manufacture and supply a first-to-file generic topical drug product, adding another program to its growing portfolio of commercial-stage pharmaceutical products. The agreement marks the company’s sixth commercial manufacturing deal in the past 22 months, reflecting continued momentum in its business and growing demand for specialized topical drug development and manufacturing services.
The latest addition also represents an expansion of MedPharm’s commercial capabilities into first-to-file generic topical products. Manufacturing will take place at the company’s 110,000-square-foot facility in Durham, North Carolina. The site combines dedicated production infrastructure, analytical testing capabilities and an experienced technical team to support commercial-scale manufacturing and product supply.
“This agreement is another important step in our continued growth,” says Bill Humphries, CEO of MedPharm. “Adding a first-to-file generic topical product to our commercial portfolio demonstrates the range of programs our team can support and the strength of our specialized expertise. We look forward to working with our partner to deliver reliable commercial manufacturing and supply.”
For more information, visit medpharm.com.
Total Page Views: 3
